Abbott (US), Johnson & Johnson Private Limited (U.S.), MicroPort Scientific Corporation. (China), Boston Scientific Corporation (US)., Medtronic (US), BIOTRONIK SE & Co. KG (US), Koninklijke Philips N.V. (Netherlands), Siemens (US), AtriCure, Inc (US), Sanofi (US), Biosense Webster, Inc (US), CardioFocus. (US), BRISTOL-MYERS SQUIBB COMPANY (US), Boehringer Ingelheim International GmbH. (US), GENERAL ELECTRIC COMPANY (US), Pfizer Inc. (US) are the major companies in the Atrial Fibrillation market.
In January 2024, Medtronic launched the Arctic Front Advance Cryoballoon, a new device designed for the treatment of atrial fibrillation (AFib). This device offers enhanced precision and safety in catheter ablation procedures, helping to improve patient outcomes. In November 2022, Abbott introduced the EnSite X EP System, a cutting-edge mapping system designed to provide more accurate and efficient navigation during AFib treatments. This system integrates advanced imaging technology to enhance electrophysiological mapping and improve ablation success rates.
The countries covered in the busway market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.